非小細胞肺癌的標靶治療市場:KOL的洞察

本報告提供全球非小細胞肺癌的標靶治療市場相關調查，提供市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

現在及未來的治療流程

調查目的

EGFR及HER2抑制劑

• 已通過核准及開發平台的醫藥品
  • Tagrisso（奧希替尼、阿斯特捷利康）
  • Rybrevant（amivantamab-vmjw、Genmab/Janssen）與 Leclaza（lazertinib、Janssen）
  • Exkivity（mobocertinib，武田藥）
• 正在研究藥物
  • 奧莫替尼（江蘇恆瑞製藥）
  • ?羅替尼（江蘇恆瑞製藥）

抗體-藥物結合物

• 核准的藥品
  • Enhertz（曲妥珠單抗 deruxtecan、第一三共/阿斯特捷利康）
• 管道療法
  • Trodelvy（sacituzumab govitecan，吉利德）和 datopotamab deruxtecan（阿斯特捷利康/第一三共）
  • Patritumab deruxtecan（第一三共）
  • Tsamitamavravtansin（賽諾菲）
  • Terisotuzumab vedotin（艾伯維）

ALK 抑制劑

• 核准的治療方法 (7)
  • Alecensa（alectinib，羅氏）、Alunbrig（brigatinib，武田）和 Lorbrena/Lorviqua（lorlatinib，輝瑞）
• 管道療法
  • Ensartinib（貝達製藥/Xvocery）

KRAS 抑制劑

• 核准的藥品 (16)
  • Lumaclas/Lumiclas（Sotorasib、安進）
  • Krazati（adagrasib，Mirati Therapeutics）
• 管道療法
  • JDQ443（諾華）

MET抑制劑

• 核准的藥品
  • Tabrecta（卡馬替尼，諾華）和 Tepmetco（tepotinib，默克集團）(8)
• 管道療法
  • 沃利替尼（阿斯特捷利康/Hutchmed）

RET抑制劑

• 核准的藥品
  • Gavreto（pralsetinib，Blueprint Medicines）和 Retevmo/Retsevmo（selpercatinib，禮來）

未來治療趨勢

• 主要見解摘要

附錄

新聞

Which combination strategies do KOLs say are likely to expand use of AstraZeneca's dominant EGFR TKI therapy Tagrisso? How do KOLs assess the potential of Genmab/Janssen's Rybrevant + Janssen's Leclaza in patients with EGFR-TKI resistance? Do KOLs believe the Phase III DESTINY-Lung04 study could establish Daiichi Sankyo/AstraZeneca's ADC Enhertu as a first-line therapy? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

• 15 Sep 2023 KOL Bulletin -- Views on Phase III ALINA data for Roche's Alecensa

• 21 Sep 2023 KOL Bulletin -- Views on Phase III FLAURA2 data for AstraZeneca's Tagrisso

Table of Contents

Executive summary (6)

Current and future treatment algorithm

Research objectives (2)

EGFR and HER2 inhibitors (46)

• Approved and pipeline drugs (31)
  • Tagrisso (osimertinib; AstraZeneca) (13)
  • Rybrevant (amivantamab-vmjw; Genmab/Janssen) and Leclaza (lazertinib; Janssen) (12)
  • Exkivity (mobocertinib; Takeda) (6)
• Pipeline drugs (15)
  • Aumolertinib (Jiangsu Hansoh Pharmaceutical) (8)
  • Pyrotinib (Jiangsu Hengrui Pharmaceuticals) (7)

Antibody-drug conjugates (31)

• Approved drugs (10)
  • Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca) (10)
• Pipeline therapies (21)
  • Trodelvy (sacituzumab govitecan; Gilead) and datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo) (7)
  • Patritumab deruxtecan (Daiichi Sankyo) (5)
  • Tusamitamab ravtansine (Sanofi) (5)
  • Telisotuzumab vedotin (AbbVie) (4)

ALK inhibitors (12)

• Approved therapies (7)
  • Alecensa (alectinib; Roche), Alunbrig (brigatinib; Takeda) and Lorbrena/Lorviqua (lorlatinib; Pfizer) (7)
• Pipeline therapies (5)
  • Ensartinib (Betta Pharmaceuticals/Xvocery) (5)

KRAS inhibitors (21)

• Approved drugs (16)
  • Lumakras/Lumykras (sotorasib; Amgen) (10)
  • Krazati (adagrasib; Mirati Therapeutics) (6)
• Pipeline therapies (5)
  • JDQ443 (Novartis) (5)

MET inhibitors (15)

• Approved drugs (8)
  • Tabrecta (capmatinib; Novartis) and Tepmetko (tepotinib; Merck Group) (8)
• Pipeline therapies (7)
  • Savolitinib (AstraZeneca/Hutchmed) (7)

RET inhibitors (8)

• Approved drugs (8)
  • Gavreto (pralsetinib; Blueprint Medicines) and Retevmo/Retsevmo (selpercatinib; Lilly) (8)

Future treatment trends (8)

• Key insights summary (8)

Appendix (4)

• KOL details (4)
  • KOLs from the USA (1)
  • KOLs from Europe (2)

News (2)